2023, Volume 9
2022, Volume 8
2021, Volume 7
2020, Volume 6
2019, Volume 5
2018, Volume 4
2017, Volume 3
2016, Volume 2
2015, Volume 1
Submit a Manuscript
Publishing with us to make your research visible to the widest possible audience.
Medical Affairs and Training Department, Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan
Aims and Objective: Chondroxide gel is used topically in osteoarthritis, rheumatoid arthritis, cervical spondylosis, and frozen shoulder. This small-scale clinical survey was conducted to determine the safety and efficacy of the herbal product Chondroxide gel manufactured by Herbion Pakistan (Pvt.) Ltd. at Tulsi Medical Centre, Karachi, Pakistan. Introduction: Osteoarthritis is the most common disorder with joint pain and stiffness symptoms. Rheumatoid arthritis is a chronic inflammatory autoimmune disorder and another common reason for disability. At the same time, cervical spondylosis is a disease affecting the cervical spine, whereas a frozen shoulder often prolongs a disabling condition that can be managed by primary care. Method: This was a small-scale, open-labeled clinical survey. A total of 30 patients were enrolled in the study, out of which four patients got dropped out. 26 patients received Chondroxide gel. Statistical analysis was done by using the IBM SPSS 20. Results: Chondroxide gel was found safe and effective in treating osteoarthritis, rheumatoid arthritis, cervical spondylosis, and frozen shoulder and stated better response compared to the topical formulation available in the market. Conclusion: The results indicated improvement after applying the Chondroxide gel in patients with osteoarthritis, rheumatoid arthritis, cervical spondylosis, and frozen shoulder complaints and relieved external pain.
Chondroxide Gel, Osteoarthritis, Rheumatoid Arthritis, Cervical Spondylosis, Frozen Shoulder
Saba Fatima, Ifrah Hasan, Muhammad Junaid. (2023). Chondroxide Gel Manufactured by Herbion Pakistan (Pvt.) Ltd in Patients with Osteoarthritis, Rheumatoid Arthritis, Cervical Spondylosis, and Frozen Shoulder. International Journal of Clinical and Experimental Medical Sciences, 9(4), 60-64. https://doi.org/10.11648/j.ijcems.20230904.11
Copyright © 2023 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|1.||Dieppe, P. A. and L. S. Lohmander, Pathogenesis and management of pain in osteoarthritis. The Lancet, 2005. 365 (9463): p. 965-973.|
|2.||Arden, N. and M. C. Nevitt, Osteoarthritis: epidemiology. Best practice & research Clinical rheumatology, 2006. 20 (1): p. 3-25.|
|3.||Majithia, V. and S. A. Geraci, Rheumatoid arthritis: diagnosis and management. The American journal of medicine, 2007. 120 (11): p. 936-939.|
|4.||Hossain, S., Shamim, A., Saifuzzaman, M., Attiquzzaman, M., Hossain, G., & Raihan, O. (2020). Formulation and development of a topical combination cream for arthritis management. Tropical Journal of Pharmaceutical Research, 19 (6), 1125-1130.|
|5.||Lestini, W. F. and S. W. Wiesel, The pathogenesis of cervical spondylosis. Clinical orthopaedics and related research, 1989 (239): p. 69-93.|
|6.||Dias, R., S. Cutts, and S. Massoud, Frozen shoulder. Bmj, 2005. 331 (7530): p. 1453-1456.|
|7.||Lin, J., et al., Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. Bmj, 2004. 329 (7461): p. 324.|
|8.||Heyneman, C. A., C. Lawless-Liday, and G. C. Wall, Oral versus topical NSAIDs in rheumatic diseases. Drugs, 2000. 60 (3): p. 555-574.|
|9.||Vaile, J. H. and P. Davis, Topical NSAIDs for musculoskeletal conditions. Drugs, 1998. 56 (5): p. 783-799.|
|10.||Mazieres, B., et al., Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. The Journal of rheumatology, 2001. 28 (1): p. 173-181.|
|11.||Bana, G., et al., Chondroitin sulfate in the management of hip and knee osteoarthritis: an overview. Advances in Pharmacology, 2006. 53: p. 507-522.|
|12.||Wang, H., & Ma, B. (2022). Healthcare and scientific treatment of knee osteoarthritis. Journal of Healthcare Engineering, 2022.|
|13.||Wen, J., Li, H., Dai, H., Hua, S., Long, X., Li, H., ... & Xu, C. (2023). Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management. Materials Today Bio, 100597.|
|14.||Zhang, Y., Gao, Z., Chao, S., Lu, W., & Zhang, P. (2022). Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis. Drug Delivery, 29 (1), 1934-1950.|
|15.||Rodríguez-Merchán, E. C., De la Corte-Rodríguez, H., & Román-Belmonte, J. M. (2020). Initial Treatment of Knee Osteoarthritis: Oral and Topical Drugs. Comprehensive Treatment of Knee Osteoarthritis: Recent Advances, 1-10.|